C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer
Cells · 2024
DOI: 10.3390/cells13181530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Lauren S Strathearn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 4HN, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Smad3 Protein, Transforming Growth Factor beta, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Cancer Research UK Scotland Institute, Biological Services Unit.
Abstract (Originalsprache)
Transforming Growth Factor-β (TGF-β) can have both tumour-promoting and tumour-suppressing activity in breast cancer. Elucidating the key downstream mediators of pro-tumorigenic TGF-β signalling in this context could potentially give rise to new therapeutic opportunities and/or identify biomarkers for anti-TGF-β directed therapy. Here, we identify C1orf106 (also known as innate immunity activator INAVA) as a novel TGF-β target gene which is induced in a SMAD3-dependent but SMAD2/SMAD4-independent manner in human and murine cell lines. C1orf106 expression positively correlates with tumourigenic or metastatic potential in human and murine breast cancer cell line models, respectively, and is required for enhanced migration and invasion in response to TGF-β stimulation. C1orf106 promoted self-renewal and colony formation in vitro and may promote tumour-initiating frequency in vivo. High C1orf106 mRNA expression correlates with markers of aggressiveness and poor prognosis in human breast cancer. Taken together, our findings indicate that C1orf106 may act as a tumour promoter in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 4HN, UK.
- Cancer Research UK Scotland Institute, Garscube Estate, Bearsden, Glasgow G61 1BD, UK.
- Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee DD1 4HN, UK.
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
ORCID-Profile: Lindsay C Spender, Christina Schoenherr, Ruaridh Edwards, Karen Blyth, Gareth J Inman
Förderung
- Cancer Research UK
- Cancer Research UK Scotland Institute
- Biological Services Unit
- AICR
- Dundee Cancer Centre UK
Zitieren
APA
Strathearn, L. S., Spender, L. C., Schoenherr, C., Mason, S., Edwards, R., Blyth, K., & Inman, G. J. (2024). C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer. Cells. https://doi.org/10.3390/cells13181530
Vancouver
Strathearn LS, Spender LC, Schoenherr C, Mason S, Edwards R, Blyth K, et al. C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer. Cells. 2024. doi:10.3390/cells13181530
BibTeX
@article{Strathearn2024,
author = {Strathearn, Lauren S and Spender, Lindsay C and Schoenherr, Christina and Mason, Susan and Edwards, Ruaridh and Blyth, Karen and Inman, Gareth J},
title = {C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13181530}
}
EUVIMED